恩替卡韦联合和络舒肝胶囊治疗代偿期乙肝肝硬化的临床效果

Abstract
Figure/Table
References (15)
Related Citation (3)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Entecavir combined with Heluoshugan Capsules treating hepatitis B cirrhosis of compensated stage.Methods 82 patients with hepatitis B cirrhosis of compensated stage diagnosed and treated by department of gastroenterology in Central Hospital of Jiaozhou of Qingdao City from June 2011 to May 2012 were selected and they were randomly divided into treatment group of 41 cases and control group of 41 cases.Control group was treated with oral Entecavir Disket 0.5 mg,once a day,while the treatment group was treated with oral Heluoshugan Capsules for 5 capsules,three times a day,and taking Heluoshugan Capsules for 2 months and stopping 1 month and then continued to take according to the law,and both groups received 48 months treatment.Treatment effect between two groups was compared.Results Albumin(Alb)level in two groups were significantly different(t=6.351,P=0.017),the treatment group was better than the control group;the level of serum hyaluronie acid(HA),Laminin(LN),procollagen typeⅢ(PC-Ⅲ)and collagen typeⅣ-C(Ⅳ-C)were decreased significantly in treatment group than in control group, and the above-mentioned indexes were better than those in control group(P＜0.01).The negative conversion rate of treatment group(41.4%)was significantly higher than that of control group(14.6%)(P＜0.01).There was a statistical difference of the portal vein diameter between two groups(P＜0.01),but there was no significant difference in negative conversion rate of HBV-DNA(P＞0.05).Conclusion Entecavir combined with Heluoshugan Capsules treating hepatitis B cirrhosis of compensated stage can improve liver function,suppress viral replication persistently,and can delay or even reverse the progression of liver fibrosis,and it has clinical application value.

Key words： Entecavir Heluoshugan Capsules Compensated stage Hepatitis B cirrhosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I3/24

[1]	Tseng PL，Lu SN，Tung HD，et al.Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis[J].J Viral Hepat，2005，12（4）：386-392.
[2]	占春玲.乙肝肝硬化并发原发性肝癌危险因素的logistic回归分析[J].医学临床研究，2016，33（9）：11-13.
[3]	Abu-Amara M，Feld JJ.Does antiviral therapy for chronic hepatitis B reduce the risk of hepatcel lular carcinoma?[J]. Semin Liver Dis，2013，33（2）：157-166.
[4]	中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）[J].中华临床感染病杂志，2011，4（1）：1-13.
[5]	黄英男，吴昊.乙型肝炎肝硬化抗病毒治疗研究进展[J].复旦学报（医学版），2013，40（2）：233-238.
[6]	张敏，杨丽莎，彭德珍，等.慢性HBV感染不同免疫状态及乙肝肝硬化外周血T、B细胞亚群和NK细胞的变化及意义[J].实用医学杂志，2014，30（20）：3233-3236.
[7]	Kim JK，Ma DW，Lee KS，et al.Assessment of hepatic fibrosisregression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents[J].J Korean Med Sci，2014，29（4）：570-575.
[8]	应灵军，陈华忠，张建伟，等.代偿期乙型肝炎肝硬化患者长期抗病毒治疗后临床特点和肝脏组织学改变[J].中华临床感染病杂志，2016，9（1）：13-16.
[9]	Cheng Y，Ping J，Liu C，et al．Study on effects of extracts from Salvia Miltiorrhiza and Curcuma Longa in inhibiting phosphorylated extracellular signal regulated kinase expression in rate hepatic stellate cells[J]．Chin J Integr Med，2006，12（3）：207-211．
[10]	王元，钟森，陈婧.和络舒肝胶囊治疗乙型肝炎肝纤维化疗效的系统评价[J].中国循证医学杂志，2016，16（8）：962-971.
[11]	许方沥.慢性乙型肝炎中医证候分型的文献评价[J].实用肝脏病杂志，2008，11（2）：109-112.
[12]	胡义扬，刘成海．肝纤维化的中医药治疗和研究值得关注[J]．中西医结合肝病杂志，2008，18（1）：l-4．
[13]	黄志杰，曾翠萍.恩替卡韦联合安络化纤丸治疗HBeAg阳性慢性乙型肝炎肝纤维化134例[J].中西医结合肝病杂志，2016，26（2）：74-75.
[14]	尚杰云.健脾活血利水方治疗乙肝肝硬化对脾脏、门静脉主干内径的影响[J].中国中医药现代远程教育，2016，14（5）：32-33.
[15]	朱方石，金实，汪悦.肝硬化中医证型与肝纤维化指标相关性的研究[J].辽宁中医杂志，2000，11（27）：481-482.